Autoimmune diseaseImmunology & inflammationNeurology & neurodegenerationRare disease PKPD

Ravulizumab exposure and free C5 suppression

Reference paper ↗

A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.

Therapeutic
Ravulizumab
Modality
Monoclonal antibody
Target
Complement C5
Disease
Neuromyelitis optica spectrum disorder
Model type
PKPD

Complete model workspace

Checking workspace access…

Parameters
3
States
3
Equations
3
Derived outputs
125

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Body weight 40 to <60 kg week-50 PK/free-C5

How do weight-based ravulizumab regimens maintain exposure and suppression of free C5? Explore this intervention regimen through Central ravulizumab amount, Free complement C5, Cumulative ravulizumab exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–352 day; step 1

InputDefaultAvailable range
Apparent distribution volume2.471 L1.235–3.706 L
Elimination rate constant0.01575 1/day0.007877–0.02363 1/day
C5 suppression rate8.672 1/day4.336–13.01 1/day

Expected readouts

Central-compartment drug amount (mg) · Free complement C5 (ug/mL) · Exposure (AUC) (ug*day/mL)

Adjustable model parameters

This public explorer exposes 3 curated parameters. Sign in to edit all 3 declared model parameters.

How the model represents the biology

A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.

How do ravulizumab exposure and the independently modeled C5 state evolve?An intravenous ravulizumab dose enters a central exposure state, which undergoes first-order elimination and accumulates exposure. A separate free-C5 state undergoes first-order decline without any ravulizumab-dependent term or recovery input.BIOLOGY OVERVIEWHow do ravulizumab exposure and the independently modeled C5 state evolve?IV ravulizumabDose to central stateRavulizumab exposureCentral antibody amountAntibody eliminationFirst-order central lossCumulative exposureCentral concentration integralFree complement C5Independent target stateModeled C5 declineExposure-independentfirst-order lossPRIMARY READOUTSCentral ravulizumab amountCentral ravulizumab amountFree C5Free C5Cumulative ravulizumab exposureCumulative ravulizumab exp…

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Ravulizumab-dependent C5 binding or suppression, C5 production or recovery, target-mediated clearance, downstream complement biology, and NMOSD outcomes are not represented.

Modeled relationships (4)
  • IV ravulizumab → Ravulizumab exposure: IV input (flow)
  • Ravulizumab exposure → Antibody elimination: first-order (loss)
  • Ravulizumab exposure → Cumulative exposure: integrates C (production)
  • Free complement C5 → Modeled C5 decline: first-order (loss)

Modeled relationships: IV ravulizumab to Ravulizumab exposure: IV input (flow); Ravulizumab exposure to Antibody elimination: first-order (loss); Ravulizumab exposure to Cumulative exposure: integrates C (production); Free complement C5 to Modeled C5 decline: first-order (loss).

Primary readouts: Central ravulizumab amount; Free C5; Cumulative ravulizumab exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID ortiz_2024_ravulizumab_nmosd_pkpd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics